TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28923845

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) <4 ng/L and cardiovascular risk factors <2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) with additional criteria of no change or a decrease between baseline and 2 h hs-cTnI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of hs-cTnI
Number of subjects: 0
Study: 28923906

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 28924018

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg daily until cGVHD progression)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg daily)
Number of subjects: 42
Study: 28925027

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) drug levels <200 ng/ml or undetectable desethylchloroquine
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires (MASRI <80% or MMAS-8 <6)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Physician assessment
Number of subjects: 305
Study: 28925320

Group type: EXPERIMENTAL
Intervention: Systematic preoperative sinus CT checklist
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard preoperative review (preimplementation)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Postimplementation review with checklist
Number of subjects: 57
Study: 28925785

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy after four cycles (FCR4)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy at end of treatment (EOT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy
Number of subjects: 52
Study: 28926513

Group type: EXPERIMENTAL
Intervention: 50 mg phytoSERM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 mg phytoSERM
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28927372

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate regular medication
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Three or more potentially inappropriate medications
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Medication needing surveillance according to NORGEP-NH
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Regular use of psychotropic drugs
Number of subjects: 881

Group type: COMPARATOR
Intervention: Potentially inappropriate regular medication (females)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Three or more concomitant psychotropic medications (females)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Use of multiple psychoactive drugs
Number of subjects: 881
Study: 28927395

Group type: EXPERIMENTAL
Intervention: Community health worker monitoring for signs of HRPB
Number of subjects: 7050

Group type: EXPERIMENTAL
Intervention: Risk stratification based on signs and symptoms of HRPB
Number of subjects: 7050
Study: 28927712

Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 111

Group type: COMPARATOR
Intervention: No Rufinamide
Number of subjects: 111
Study: 28928173

Group type: EXPERIMENTAL
Intervention: First-line anti-TB treatment
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis
Number of subjects: 268
Study: 28928706

Group type: EXPERIMENTAL
Intervention: EMG-driven NMES-robotic arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional physical treatments
Number of subjects: 0
Study: 28928789

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) treatment during hospitalization
Number of subjects: 524
Study: 28930079

Group type: EXPERIMENTAL
Intervention: HIV-infected women with excess EAT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-HIV-infected women
Number of subjects: 82
Study: 28930852

Group type: EXPERIMENTAL
Intervention: semi-immersive virtual training with body shadows (S-IVTS group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: semi-immersive virtual training without body shadows (S-IVT group)
Number of subjects: 20
Study: 28931244

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 884

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 884
Study: 28931437

Group type: EXPERIMENTAL
Intervention: MitraClip intervention
Number of subjects: 45
Study: 28931498

Group type: EXPERIMENTAL
Intervention: Smartphone app (ColoprAPP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (regular colonoscopy preparation leaflet)
Number of subjects: 25
Study: 28931501

Group type: EXPERIMENTAL
Intervention: Cascade screening for HBOC and LS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-based communication, coping, and decision support intervention
Number of subjects: 0
Study: 28931529

Group type: EXPERIMENTAL
Intervention: ECG strain (n=168, 2.6%)
Number of subjects: 6441

Group type: EXPERIMENTAL
Intervention: ECG strain
Number of subjects: 6441
Study: 28932269

Group type: EXPERIMENTAL
Intervention: IBS-D Daily Symptom Diary and Event Log
Number of subjects: 434
Study: 28932270

Group type: EXPERIMENTAL
Intervention: Open-label rifaximin 550 mg three times daily for 2 weeks
Number of subjects: 2579

Group type: EXPERIMENTAL
Intervention: Double-blind rifaximin (two 2-week courses)
Number of subjects: 2579

Group type: COMPARATOR
Intervention: Placebo (two 2-week courses)
Number of subjects: 2579
Study: 28932579

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 300
Study: 28932752

Group type: EXPERIMENTAL
Intervention: rhBMP-12/ACS
Number of subjects: 20

Group type: COMPARATOR
Intervention: SOC control
Number of subjects: 20
Study: 28932928

Group type: EXPERIMENTAL
Intervention: Single 4.1 mg oral solution dose of ixazomib
Number of subjects: 0
Study: 28933971

Group type: EXPERIMENTAL
Intervention: Fp MDPI 200 mcg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FS MDPI 200/12.5 mcg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fp DPI 500 mcg (250 mcg × 2 inhalations)
Number of subjects: 40

Group type: COMPARATOR
Intervention: FS DPI 500/50 mcg
Number of subjects: 40
Study: 28934175

Group type: EXPERIMENTAL
Intervention: Body Adiposity Index (BAI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bioelectrical Impedance Analysis (BIA)
Number of subjects: 96
Study: 28934680

Group type: EXPERIMENTAL
Intervention: Gandotinib (LY2784544), a potent inhibitor of JAK2 activity
Number of subjects: 0
Study: 28934789

Group type: EXPERIMENTAL
Intervention: Chronic WAD patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study: 28934932

Group type: EXPERIMENTAL
Intervention: Early KP group (≤3 years duration)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Established KP group (>3 years)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: No KP group
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Baseline data
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Subsequent prospective data (Year 1 and Year 3)
Number of subjects: 400
Study: 28935032

Group type: EXPERIMENTAL
Intervention: T2MI definition requiring the presence of coronary artery disease
Number of subjects: 4015

Group type: COMPARATOR
Intervention: T2MI definition without requiring coronary artery disease
Number of subjects: 4015
Study: 28935432

Group type: EXPERIMENTAL
Intervention: ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks (with or without ribavirin)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: ravidasvir plus sofosbuvir with ribavirin for 12 or 16 weeks
Number of subjects: 298
Study: 28935451

Group type: EXPERIMENTAL
Intervention: Ideal group (BCLC stage 0-A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nonideal group (BCLC stage beyond A)
Number of subjects: 65
Study: 28935452

Group type: EXPERIMENTAL
Intervention: 3D image-guidance system (Explorer)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (median 4 months, range 2-24 months)
Number of subjects: 50
Study: 28935620

Group type: EXPERIMENTAL
Intervention: 3-month physical activity track
Number of subjects: 71

Group type: COMPARATOR
Intervention: 3-month dietary track
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall satisfaction with ALIVE
Number of subjects: 71
Study: 28935628

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28935629

Group type: EXPERIMENTAL
Intervention: Lyon Advance Care Planning Survey - Adolescent Version
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lyon Advance Care Planning Survey - Surrogate Version
Number of subjects: 96
Study: 28935718

Group type: EXPERIMENTAL
Intervention: Cooling therapy (prematurely discontinued)
Number of subjects: 10
Study: 28935847

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 28936121

Group type: EXPERIMENTAL
Intervention: Education intervention consisting of a two-day seminar and monthly coaching sessions for six months.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through ethnographic fieldwork, qualitative interviews, and analysis of reflection notes.
Number of subjects: 24
Study: 28936175

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-Amphetamine
Number of subjects: 0
Study: 28936597

Group type: COMPARATOR
Intervention: Immediate extubation
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Terminal weaning
Number of subjects: 248
Study: 28936602

Group type: EXPERIMENTAL
Intervention: Mom Power (MP) Intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 75
Study: 28936626

Group type: EXPERIMENTAL
Intervention: Frailty (values ≥ 5)
Number of subjects: 5021

Group type: EXPERIMENTAL
Intervention: Overall ICU mortality
Number of subjects: 5021

Group type: EXPERIMENTAL
Intervention: Overall 30-day mortality
Number of subjects: 5021

Group type: EXPERIMENTAL
Intervention: Patients not receiving specific ICU procedures (ventilation, vasoactive drugs, renal replacement therapy)
Number of subjects: 5021

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Number of subjects: 5021
Study: 28936952

Group type: EXPERIMENTAL
Intervention: Injection test with esophageal balloon catheter
Number of subjects: 20
Study: 28937974

Group type: EXPERIMENTAL
Intervention: Somatic mutation burden
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Missense mutation load
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Neoantigen burden
Number of subjects: 664
Study: 28938419

Group type: EXPERIMENTAL
Intervention: FMV urinary LH
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Urinary LH
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Urinary LH (cut-off SD score of 2)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Urinary concentrations of LH after 3 months of GnRH treatment
Number of subjects: 868
Study: 28938424

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Age-stratified linear regression analyses
Number of subjects: 683
Study: 28938429

Group type: EXPERIMENTAL
Intervention: Preconception impaired glucose tolerance (IGT)
Number of subjects: 1508
Study: 28938478

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Glucose-insulin infusion
Number of subjects: 28
Study: 28938891

Group type: EXPERIMENTAL
Intervention: Culture-expanded, autologous, bone marrow-derived MSCs
Number of subjects: 33
Study: 28938918

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) at dose level 3 (36 Gy/3)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) in combination with pazopanib
Number of subjects: 13
Study: 28939374

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 428
Study: 28939487

Group type: EXPERIMENTAL
Intervention: Plasma Hsp90α measurement
Number of subjects: 1647
Study: 28939546

Group type: EXPERIMENTAL
Intervention: Smart technology intervention (daily measurements with smartphone-compatible ECG device, BP monitor, weight scale, activity tracker; two electronic visits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smart technology intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care (four outpatient clinic visits)
Number of subjects: 0
Study: 28939558

Group type: EXPERIMENTAL
Intervention: BVD-523 (ulixertinib), a novel, reversible, ATP-competitive ERK1/2 inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BVD-523 (ulixertinib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BRAF and MEK-targeted combination therapy
Number of subjects: 0
Study: 28939688

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Fitness (CRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BMI categories
Number of subjects: 0
Study: 28940225

Group type: EXPERIMENTAL
Intervention: Automated low-flow ascites pump (alfapump)
Number of subjects: 56
Study: 28940435

Group type: EXPERIMENTAL
Intervention: Counselor MI inconsistent language
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sustain talk
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MI inconsistent language (MIIN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sustain talk early in the session (deciles 1 and 2)
Number of subjects: 40
Study: 28940455

Group type: EXPERIMENTAL
Intervention: Patient risk model
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Nodule risk model
Number of subjects: 715
Study: 28940629

Group type: EXPERIMENTAL
Intervention: Alcohol use (1 drink)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Alcohol use (2 nights later)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Heavier drinking (4-5 drinks)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 73
Study: 28940967

Group type: EXPERIMENTAL
Intervention: 4-year MVPA
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: 1-year MVPA
Number of subjects: 553

Group type: COMPARATOR
Intervention: MVPA at year 1 (WL maintainers vs nonmaintainers)
Number of subjects: 553

Group type: COMPARATOR
Intervention: MVPA at year 4 (WL maintainers vs nonmaintainers)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Engagement in ≥250 min/wk of MVPA
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Engagement in <150 min/wk of MVPA
Number of subjects: 553
Study: 28941023

Group type: EXPERIMENTAL
Intervention: Daclatasvir-based regimens
Number of subjects: 1503
Study: 28941030

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 391

Group type: COMPARATOR
Intervention: Bilateral nerve-sparing robot-assisted radical prostatectomy (RARP)
Number of subjects: 391
Study: 28941036

Group type: EXPERIMENTAL
Intervention: Donor SUMO4 rs237025 AA carriers
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Combined donor CYP3A5 rs776746 and donor SUMO4 rs237025 genotypes
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: CYP3A5 mRNA expression in liver tissues
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: SUMO4 rs237025 G allele
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Activation of NF-kB
Number of subjects: 297
Study: 28941136

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for unilateral CRSsNP
Number of subjects: 190

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for bilateral CRSsNP
Number of subjects: 190
Study: 28941219

Group type: EXPERIMENTAL
Intervention: Tofacitinib (1-30 mg twice daily or 20 mg once daily)
Number of subjects: 6194
Study: 28941330

Group type: EXPERIMENTAL
Intervention: Islet preparations with a mean purity <50% (LOW purity)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Islet preparations with a mean purity ≥50% (HIGH purity)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-IT blood levels of CA 19-9 and glucagon
Number of subjects: 24
Study: 28941620

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP with 25μg Matrix-M (n=8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA ME-TRAP with 50μg Matrix-M (n=8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: ChAd63-MVA ME-TRAP alone (n=6)
Number of subjects: 22
Study: 28941623

Group type: EXPERIMENTAL
Intervention: MenACWY-D vaccine
Number of subjects: 31561
Study: 28943010

Group type: EXPERIMENTAL
Intervention: Aorfix endograft
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Proximal neck diameter
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Seal zone inner curve length
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Neck diameter stratification
Number of subjects: 205
Study: 28943279

Group type: EXPERIMENTAL
Intervention: Upper lobe-predominant emphysema (n=905)
Number of subjects: 9210

Group type: EXPERIMENTAL
Intervention: Lower lobe-predominant emphysema (n=796)
Number of subjects: 9210

Group type: EXPERIMENTAL
Intervention: Minimal emphysema (n=1,312)
Number of subjects: 9210
Study: 28943493

Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound (IVUS) performed in a non-culprit coronary artery
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Genome-wide association study of plaque morphology
Number of subjects: 846
Study: 28943515

Group type: EXPERIMENTAL
Intervention: Bleeding impacting mortality after noncardiac surgery (BIMS)
Number of subjects: 16079

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for BIMS
Number of subjects: 16079

Group type: EXPERIMENTAL
Intervention: Incidence of BIMS
Number of subjects: 16079

Group type: EXPERIMENTAL
Intervention: Clinical prediction guide for BIMS
Number of subjects: 16079
Study: 28943516

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 984
Study: 28943894

Group type: EXPERIMENTAL
Intervention: Syndrome Z in obese women with MetS
Number of subjects: 83
Study: 28944067

Group type: EXPERIMENTAL
Intervention: Probiotic intervention (two daily tablets totalling 1.4×10)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (patients without neoplastic or inflammatory disease)
Number of subjects: 15
Study: 28944597

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 15
Study: 28944613

Group type: EXPERIMENTAL
Intervention: PF-SES
Number of subjects: 0

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 0
Study: 28944714

Group type: EXPERIMENTAL
Intervention: Gymnemic acids (GA) lozenge
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 67
Study: 28945120

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28945476

Group type: EXPERIMENTAL
Intervention: Lungs recovered from uDCDDs
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Lungs assessed by 4 hours ex vivo lung perfusion (EVLP)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Lungs from brain-dead donors (control group)
Number of subjects: 502
Study: 28945839

Group type: EXPERIMENTAL
Intervention: GRANT score (based on Fuhrman grade, age, pathological nodal status, and pathological tumor size)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Already validated score systems
Number of subjects: 0
Study: 28945848

Group type: EXPERIMENTAL
Intervention: Panitumumab in combination with irinotecan
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plasma testing of cell-free DNA by BEAMing
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Emergent RAS mutations at progression
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serial analysis of plasma samples
Number of subjects: 39
Study: 28945884

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 66
Study: 28945911

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF therapy, no LXR agonist
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF therapy, LXR agonist
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-HIV-infected subjects, no LXR agonist
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-HIV-infected subjects, LXR agonist
Number of subjects: 10
Study: 28946849

Group type: EXPERIMENTAL
Intervention: S. aureus ICU acquired pneumonia
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: P. aeruginosa ICU acquired pneumonia
Number of subjects: 2000
Study: 28946874

Group type: EXPERIMENTAL
Intervention: Periurethral injection of autologous regenerative cells from adipose tissue using the Celution® system
Number of subjects: 45
Study: 28947018

Group type: EXPERIMENTAL
Intervention: Blood eosinophilia ≥2%
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Blood eosinophilia ≥300 cell/microliter
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Blood eosinophilia <2%
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Blood eosinophilia ≥2% and ≥300 cell/microliter
Number of subjects: 207
Study: 28947346

Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program
Number of subjects: 9473
Study: 28947452

Group type: EXPERIMENTAL
Intervention: Various imaging modalities for the assessment of hand OA
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Functional tests, joint assessment, medical assessment, pain sensitisation tests, ultrasound, CT, MRI, conventional radiographs, fluorescence optical imaging, blood and urine samples, self-reported demographic factors, OA-related questionnaires
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cross-sectional analyses
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Longitudinal data
Number of subjects: 300
Study: 28947463

Group type: EXPERIMENTAL
Intervention: Multifaceted social marketing intervention targeting GPs
Number of subjects: 0
Study: 28947467

Group type: EXPERIMENTAL
Intervention: Dermatological diagnosis
Number of subjects: 223
Study: 28947562

Group type: EXPERIMENTAL
Intervention: Early low-risk survivors (within 6 weeks)
Number of subjects: 12243

Group type: EXPERIMENTAL
Intervention: Late low-risk survivors (within 1 year)
Number of subjects: 12243

Group type: EXPERIMENTAL
Intervention: Factors associated with being an early and late postdischarge survivor
Number of subjects: 12243